Immune checkpoint inhibitors (ICI), such as anti-programmed cell death-1 (PD-1)/PD-1 ligand-1 (PD-L1) antibodies, have achieved breakthrough results in long-term survival in many cancers [6–11]. Here, PDCD1 is linked to cancer.